Danaher Expands Diagnostics Offerings Via $338 Mil. IRIS Acquisition
This article was originally published in The Gray Sheet
Firm will combine IRIS International with its Beckman Coulter diagnostics unit. Deal adds leading worldwide provider of automated urine microscopy and chemistry systems, including IRIS’ fully-automated iQ bench-top analyzer for urine microscopy.
You may also be interested in...
Device companies raised a total of $801 million in 2012’s third quarter, an 18% drop from Q2’s $977 million. Approximately $2.6 billion was spent on device acquisitions, exactly $2 billion less than Q2’s total. Diagnostic/research company financings totaled $484 million during Q3 2012, up from last quarter’s $336 million. And while diagnostic/research M&A activity was not as prolific as last quarter, tech transfer deals are seeing a resurgence.
Clinical laboratories in the US and Europe are facing pressure from all sides as budget cuts and staffing shortages compete with a growing demand for ever-more-sophisticated lab tests to serve an aging population. As a result, lab directors are seeking innovative ways to improve efficiency and do more with less, and those goals are driving innovation in technology-based solutions such as laboratory automation and informatics. These solutions are increasingly becoming integrated into the total laboratory process – encompassing not only sample analysis, but also up- and downstream workflows – paving the way for the fully integrated, automated lab of the future.
The firm, soon to be acquired by Danaher, is pursuing a major data collection effort to gain reimbursement for its ultrasensitive prostate cancer assay, following a 300-patient trial to support 510(k) clearance.